Oral News and Research

RSS

Researchers gain new insights into potential treatment for Alzheimer's disease

It is estimated that about 35 million people worldwide currently suffer from dementia and it is expected that the number will increase to 135 million by the year 2050. The disease is already one of the most common health problems in the elderly, which is why experts predict that the numbers of people affected will increase over time.

8 Dec 2014

Oral targeted drug shows encouraging activity in patients with relapsed or resistant AML

An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) - a poor-prognosis group with few options - report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center.

8 Dec 2014

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells.

8 Dec 2014

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82).

7 Dec 2014

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Novel treatments show promising results in patients with different hematologic disorders

In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.

7 Dec 2014

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes.

7 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

NIHR recognises research study that aims to develop simple saliva test for gum diseases

A research study at Plymouth University Peninsula School of Dentistry (UK) which aims to develop a simple saliva test for gum diseases, has been recognised by the National Institute of Health Research, which has included the study in its portfolio.

5 Dec 2014

Simple treatments for Ebola patients not given sufficient priority

The widespread misconception that there are no proven treatments for Ebola virus disease has meant that simple treatments – especially intravenous fluids and electrolytes, which could reduce the number of deaths caused by the virus – have been neglected, according to a new Comment, published in The Lancet.

5 Dec 2014

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.

4 Dec 2014

TDF wins William J. Gies Award for Outstanding Achievement

Tufts Dental Facilities Serving Individuals with Disabilities, a network of clinics that provides comprehensive oral health care to adults and children with intellectual, developmental, or acquired disabilities, has been announced as the winner of the William J. Gies Award for Outstanding Achievement by an Academic Dental Institution, part of the William J. Gies Awards for Vision, Innovation and Achievement.

3 Dec 2014

Experts report three key topics that may make difference in the battle against Alzheimer's disease

Detection, prevention, and preclinical treatment are three key areas that may make a difference in the battle to reduce the rapid rise of new Alzheimer's disease (AD) cases every year. These three topics are the focus of an important new supplement to the Journal of Alzheimer's Disease.

3 Dec 2014

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Monash University and 60P Australia Pty Ltd, a subsidiary of 60° Pharmaceuticals LLC, have announced today an exclusive partnering deal, with 60P obtaining rights to develop the drug Fenretinide for dengue fever.

2 Dec 2014

BioPharmX submits request for pre-IND meeting to FDA for topical antibiotic acne compound

BioPharmX Corporation, a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration for the company's topical antibiotic acne compound currently under development.

2 Dec 2014

Research findings have major implications for public dental health resources, costs for patients

The latest research from the University of Adelaide challenges current thinking on whether many people with tooth loss really need dentures.

2 Dec 2014

Kentucky governor, Lt. governor unveil multidisciplinary health care home for children

Kentucky Gov. Steve Beshear and Lt. Gov. Crit Luallen today (Dec. 1) announced an innovative public/private partnership between Community Dental, a nonprofit of Kentucky, and University of Louisville Pediatrics to provide a multidisciplinary health care home for Kentucky children enrolled in the Medicaid program.

2 Dec 2014

Ligand indazole chloride improves motor function, study shows

Multiple sclerosis (MS), an autoimmune disease of the brain and spinal cord, affects about 2.3 million people worldwide (400,000 in the United States). Affecting more women than men, it can be seen at any age, although it is most commonly diagnosed between the ages of 20 and 40.

2 Dec 2014

Oral News and Research

Researchers gain new insights into potential treatment for Alzheimer's disease

Oral targeted drug shows encouraging activity in patients with relapsed or resistant AML

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

Novel targeted therapies and treatment combinations for leukemia

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Novel treatments show promising results in patients with different hematologic disorders

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

NIHR recognises research study that aims to develop simple saliva test for gum diseases

Simple treatments for Ebola patients not given sufficient priority

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

TDF wins William J. Gies Award for Outstanding Achievement

Experts report three key topics that may make difference in the battle against Alzheimer's disease

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

BioPharmX submits request for pre-IND meeting to FDA for topical antibiotic acne compound

Research findings have major implications for public dental health resources, costs for patients

Kentucky governor, Lt. governor unveil multidisciplinary health care home for children

Ligand indazole chloride improves motor function, study shows

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News